SAINT LAURENT, Quebec, April 08, 2024 IntelGenx Corp. today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease patients in the Phase 2 clinical.
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ?MONTPARK' Clinical Trial lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator: Greetings. Welcome to IntelGenx’s Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.